Savara Inc.
SVRA
SVRA: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
moreShow SVRA Financials
Recent trades of SVRA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SVRA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Dry powder vancomycin compositions and associated methods Feb. 18, 2020
-
Patent Title: Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis Nov. 12, 2019
-
Patent Title: Dry powder vancomycin compositions and associated methods Sep. 24, 2019
-
Patent Title: Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Sep. 10, 2019
-
Patent Title: Dry powder vancomycin compositions and associated methods Feb. 21, 2017
Federal grants, loans, and purchases
Followers on SVRA's company Twitter account
Number of mentions of SVRA in WallStreetBets Daily Discussion
Recent insights relating to SVRA
Recent picks made for SVRA stock on CNBC
ETFs with the largest estimated holdings in SVRA
Flights by private jets registered to SVRA